Sartorius Stedim Biotech (DIM) Resumen de Acciones
Sartorius Stedim Biotech S.A. se dedica a la producción y venta de instrumentos y consumibles para la industria biofarmacéutica en todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
DIM Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Sartorius Stedim Biotech S.A.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | €185.50 |
| Máximo en las últimas 52 semanas | €224.00 |
| Mínimo de 52 semanas | €150.00 |
| Beta | 1.14 |
| Cambio en 1 mes | -0.11% |
| Variación en 3 meses | 14.93% |
| Cambio de 1 año | 4.51% |
| Variación en 3 años | -24.04% |
| Variación en 5 años | -64.11% |
| Variación desde la OPV | 2,157.15% |
Noticias y actualizaciones recientes
Sartorius Stedim Biotech S.A. Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Sartorius Stedim Biotech S.A. ( EPA:DIM ) filed its half-yearly result this time...
DIM: Bioprocessing Recovery Signals Will Support Constructive Outlook Despite Higher Sector Risk
The analyst price target for Sartorius Stedim Biotech has been trimmed by €7.93 to €232.21, as analysts factor in slightly higher risk, a modestly lower profit margin outlook, and updated sector views that still identify early signs of recovery in bioprocessing. Analyst Commentary Recent commentary on Sartorius Stedim Biotech reflects a mix of optimism about early recovery signals in bioprocessing and caution about sector risk, which feeds directly into how analysts are thinking about valuation, execution, and growth over the medium term.Earnings Miss: Sartorius Stedim Biotech S.A. Missed EPS By 7.2% And Analysts Are Revising Their Forecasts
It's been a sad week for Sartorius Stedim Biotech S.A. ( EPA:DIM ), who've watched their investment drop 14% to €162 in...Recent updates
Sartorius Stedim Biotech S.A. Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Sartorius Stedim Biotech S.A. ( EPA:DIM ) filed its half-yearly result this time...DIM: Bioprocessing Recovery Signals Will Support Constructive Outlook Despite Higher Sector Risk
The analyst price target for Sartorius Stedim Biotech has been trimmed by €7.93 to €232.21, as analysts factor in slightly higher risk, a modestly lower profit margin outlook, and updated sector views that still identify early signs of recovery in bioprocessing. Analyst Commentary Recent commentary on Sartorius Stedim Biotech reflects a mix of optimism about early recovery signals in bioprocessing and caution about sector risk, which feeds directly into how analysts are thinking about valuation, execution, and growth over the medium term.Earnings Miss: Sartorius Stedim Biotech S.A. Missed EPS By 7.2% And Analysts Are Revising Their Forecasts
It's been a sad week for Sartorius Stedim Biotech S.A. ( EPA:DIM ), who've watched their investment drop 14% to €162 in...A Look At The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)
Key Insights Sartorius Stedim Biotech's estimated fair value is €191 based on 2 Stage Free Cash Flow to Equity With...DIM: Bioprocessing Recovery Expectations Will Drive Constructive Outlook Despite Recent Downgrades
Narrative Update: Sartorius Stedim Biotech The analyst fair value estimate for Sartorius Stedim Biotech has edged from about €241 to €240 as analysts factor in recent downgrades that point to the bioprocessing recovery and recent share outperformance already being reflected in the current price. Analyst Commentary Recent research updates around Sartorius Stedim Biotech are clustered around the view that the current share price already captures a meaningful part of the expected recovery in bioprocessing.What Is Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Doing?
Sartorius Stedim Biotech S.A. ( EPA:DIM ) saw significant share price movement during recent months on the ENXTPA...DIM: Bioprocessing Recovery Expectations Will Shape Constructive Outlook Despite Rating Downgrades
Analysts have trimmed their fair value estimate for Sartorius Stedim Biotech by a fraction to about €241, reflecting a mix of more cautious ratings after recent share outperformance and recovery expectations in bioprocessing that are now seen as better reflected in the price, even as some targets, such as the €250 level, have edged higher. Analyst Commentary Recent research paints a mixed picture for Sartorius Stedim Biotech, with price targets clustering in the €240 to €250 range and ratings moving toward more neutral stances after the share price recovery.Why We're Not Concerned About Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price
Sartorius Stedim Biotech S.A.'s ( EPA:DIM ) price-to-earnings (or "P/E") ratio of 79.2x might make it look like a...DIM: Raised 2025 Guidance And Updated Assumptions Will Shape Balanced Outlook
Analysts have nudged their price expectations for Sartorius Stedim Biotech higher, with one recent move lifting a target to €250 from €230. This change reflects updated assumptions around discount rates, growth and P/E inputs.DIM: Raised 2025 Guidance Will Support Stronger Prospects Ahead
Analysts have modestly raised their price target for Sartorius Stedim Biotech to approximately €241 from about €237, citing a slightly higher assumed future valuation multiple that more than offsets marginally lower growth and profitability expectations. What's in the News Sartorius Stedim Biotech raised its 2025 sales revenue growth guidance to around 9 percent, up from a prior forecast of 7 percent plus or minus 2 percentage points.Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...DIM: Higher Future Multiple Will Support Stronger Prospects Ahead
Analysts have raised their price target for Sartorius Stedim Biotech by approximately €5 to around €237, citing slightly improved profit margin expectations and a willingness to apply a higher future price-to-earnings multiple, despite modestly softer revenue growth forecasts. What's in the News Sartorius Stedim Biotech raised its 2025 sales revenue growth guidance to around 9 percent, up from the prior forecast of 7 percent with a plus/minus 2 percentage point range (company guidance).High Consumable Demand And Regulatory Standards Will Drive Future Success
Analysts have modestly raised their price target for Sartorius Stedim Biotech from €229.62 to €231.92. They cited improved revenue growth and higher profit margin projections as key drivers for the adjustment.Is Sartorius Stedim Biotech S.A. (EPA:DIM) Potentially Undervalued?
Sartorius Stedim Biotech S.A. ( EPA:DIM ) led the ENXTPA gainers with a relatively large price hike in the past couple...High Consumable Demand And Regulatory Standards Will Drive Future Success
Analysts have slightly lowered their price target for Sartorius Stedim Biotech from €233.31 to €229.62, citing minor adjustments in discount rates and projected revenue growth. What's in the News Sartorius Stedim Biotech and Bio Usawa Biotechnology announced a strategic partnership to accelerate Africa's biopharmaceutical industry.Is There An Opportunity With Sartorius Stedim Biotech S.A.'s (EPA:DIM) 21% Undervaluation?
Key Insights The projected fair value for Sartorius Stedim Biotech is €221 based on 2 Stage Free Cash Flow to Equity...
Increased Order Intake And Efficiency Drive Future Growth Amidst Global Challenges
Increased order intake for consumables indicates future recurring revenue stability as customer destocking improves, highlighting positive growth trends.Rentabilidad de los accionistas
| DIM | FR Life Sciences | Mercado FR | |
|---|---|---|---|
| 7D | 2.3% | 0.5% | -1.1% |
| 1Y | 4.5% | 2.2% | 4.4% |
Rentabilidad vs. Industria: DIM superó a la industria French Life Sciences, que obtuvo un rendimiento del 2.2% el año pasado.
Rentabilidad vs. Mercado: DIM igualó el mercado French, que obtuvo un rendimiento del 4.4% el año pasado.
Volatilidad de los precios
| DIM volatility | |
|---|---|
| DIM Average Weekly Movement | 5.5% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in FR Market | 10.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Precio estable de las acciones: DIM no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado French.
Volatilidad a lo largo del tiempo: La volatilidad semanal de DIM (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1978 | 10,477 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. se dedica a la producción y venta de instrumentos y consumibles para la industria biofarmacéutica en todo el mundo. La empresa ofrece diversos productos, como líneas celulares; medios de cultivo celular; biorreactores; reactivos; terapias avanzadas; y una gama de productos para procesos de separación, purificación y concentración, así como productos y sistemas para el almacenamiento y transporte de productos biológicos intermedios y acabados. También ofrece servicios de gestión de fluidos; instrumentos de interferometría de biocapas; instrumentos para pruebas microbiológicas, pruebas de esterilidad y control del aire; productos para pipetas; sensores y analizadores; instrumentos de cribado; herramientas de análisis de biomoléculas; sistemas de cromatografía intensificada y por lotes; software de gestión de datos de laboratorio y de flotas; análisis e imágenes de células vivas; soluciones de resonancia plasmónica superficial; sistemas de purificación de agua; y productos de pesaje.
Resumen de fundamentos de Sartorius Stedim Biotech S.A.
| Estadísticas fundamentales de DIM | |
|---|---|
| Capitalización bursátil | €18.05b |
| Beneficios(TTM) | €292.60m |
| Ingresos (TTM) | €3.01b |
¿Está DIM sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de DIM | |
|---|---|
| Ingresos | €3.01b |
| Coste de los ingresos | €1.66b |
| Beneficio bruto | €1.35b |
| Otros gastos | €1.06b |
| Beneficios | €292.60m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
Oct 22, 2026
| Beneficios por acción (BPA) | 3.01 |
| Margen bruto | 44.87% |
| Margen de beneficio neto | 9.74% |
| Ratio deuda/patrimonio | 52.5% |
¿Cómo se ha desempeñado DIM a largo plazo?
Ver rendimiento histórico y comparativaDividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/17 10:25 |
| Precio de las acciones al final del día | 2026/08/14 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Sartorius Stedim Biotech S.A. está cubierta por 25 analistas. 13 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Charles Pitman | Barclays |
| Susannah Ludwig | Bernstein |
| Nithya Balasubramanian | Bernstein |